Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company's products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ICEL
- CUSIP: N/A
- Web: www.cellulardynamics.com
- 50 Day Moving Avg: $14.00
- 200 Day Moving Avg: $8.00
- 52 Week Range: $5.00 - $17.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.00
- P/E Growth: 0
- Net Margins: -88.12%
- Return on Equity: -57.59%
- Return on Assets: -38.09%
- Average Volume: 175,175 shs.
Frequently Asked Questions for Cellular Dynamics International (NASDAQ:ICEL)
What is Cellular Dynamics International's stock symbol?
Cellular Dynamics International trades on the NASDAQ under the ticker symbol "ICEL."
How were Cellular Dynamics International's earnings last quarter?
Cellular Dynamics International Inc (NASDAQ:ICEL) posted its quarterly earnings data on Thursday, March, 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.08. The company earned $6.60 million during the quarter, compared to analysts' expectations of $5 million. Cellular Dynamics International had a negative return on equity of 57.59% and a negative net margin of 88.12%. View Cellular Dynamics International's Earnings History.
Who are some of Cellular Dynamics International's key competitors?
Some companies that are related to Cellular Dynamics International include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Portola Pharmaceuticals (PTLA), Galapagos NV (GLPG), ACADIA Pharmaceuticals (ACAD) and Nektar Therapeutics (NKTR).
How do I buy Cellular Dynamics International stock?
Shares of Cellular Dynamics International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Dynamics International's stock price today?
MarketBeat Community Rating for Cellular Dynamics International (NASDAQ ICEL)MarketBeat's community ratings are surveys of what our community members think about Cellular Dynamics International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cellular Dynamics International stock can currently be purchased for approximately $16.00.
Consensus Ratings for Cellular Dynamics International (NASDAQ:ICEL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cellular Dynamics International (NASDAQ:ICEL)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Cellular Dynamics International (NASDAQ:ICEL)Earnings History by Quarter for Cellular Dynamics International (NASDAQ ICEL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/5/2015||Q414||($0.44)||($0.36)||$5.00 million||$6.60 million||View||N/A|
|11/10/2014||Q314||($0.49)||($0.52)||$4.00 million||$1.80 million||View||N/A|
|8/11/2014||Q214||($0.48)||($0.54)||$4.62 million||$3.64 million||View||N/A|
|5/5/2014||Q1||($0.34)||($0.52)||$4.66 million||$2.90 million||View||N/A|
|3/10/2014||Q413||($0.30)||($0.43)||$4.27 million||$4.20 million||View||N/A|
Earnings Estimates for Cellular Dynamics International (NASDAQ:ICEL)
Current Year EPS Consensus Estimate: $-2 EPS
Next Year EPS Consensus Estimate: $-1 EPS
Dividend History for Cellular Dynamics International (NASDAQ:ICEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cellular Dynamics International (NASDAQ:ICEL)Insider Trades by Quarter for Cellular Dynamics International (NASDAQ:ICEL)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/24/2013||Floor Investors Lp Sixth||Director||Buy||40,000||$12.00||$480,000.00|| |
Headline Trends for Cellular Dynamics International (NASDAQ:ICEL)
Latest Headlines for Cellular Dynamics International (NASDAQ:ICEL)
|Very Positive Media Coverage Somewhat Likely to Impact Cellular Dynamics International (ICEL) Stock Price|
www.americanbankingnews.com - April 20 at 11:55 AM
|IPO Stock Watch: Fujifilm Acquiring Cellular Dynamics|
finance.yahoo.com - April 7 at 10:22 AM
|Cellular Dynamics Announces Partnership with The Michael J. Fox Foundation for Parkinson's Research to Provide Resources for Developing New Therapies|
finance.yahoo.com - May 25 at 11:11 PM
|Cellular Dynamics enters collaboration with Michael J. Fox Foundation|
www.bizjournals.com - May 25 at 6:05 PM
|Cellular Dynamics in Roche deal worth up to $83 million|
www.bizjournals.com - November 10 at 2:35 PM
|CELLULAR DYNAMICS INTERNATIONAL, INC. Financials|
finance.yahoo.com - May 13 at 1:04 PM
|CELLULAR DYNAMICS INTERNATIONAL, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listi|
biz.yahoo.com - May 1 at 4:28 PM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Cellular Dynamics International, Inc. And Encourages Investors To Contact The Firm For Additional Information|
finance.yahoo.com - April 6 at 6:50 PM
|Lifshitz & Miller Law Firm Announces Investigation of Auspex Pharmaceuticals, Inc., BioScrip, Inc., Catamaran Corporation, Cellular Dynamics International, Inc., First Security Group, Inc., Hyperion Therapeutics, Inc., and Norcraft Companie|
finance.yahoo.com - April 3 at 6:47 PM
|CELLULAR DYNAMICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cellular Dynamics International, Inc. Over the Proposed Sale of the Company to Fujifilm Holdings Corp. - ICEL|
finance.yahoo.com - April 3 at 5:30 PM
|WeissLaw LLP: The Cellular Dynamics International Acquisition by FUJIFILM Holdings Corporation Is the Subject of a Legal Investigation|
finance.yahoo.com - April 3 at 11:41 AM
|EQUITY ALERT: The Rosen Law Firm Announces Investigation of Cellular Dynamics International, Inc. Concerning its Proposed Sale to Fujifilm Holdings Corporation – ICEL|
finance.yahoo.com - April 1 at 7:19 PM
|SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cellular Dynamics International, Inc.|
finance.yahoo.com - April 1 at 7:05 PM
|WeissLaw LLP: Cellular Dynamics International Acquisition By FUJIFILM Holdings Corporation May Not Be In The Best Interest of ICEL Shareholders|
finance.yahoo.com - April 1 at 1:05 PM
|Ryan & Maniskas, LLP Announces Investigation of Cellular Dynamics International, Inc.|
finance.yahoo.com - April 1 at 10:43 AM
|US STOCKS-Wall St rebounds from recent losses; deals help|
finance.yahoo.com - March 30 at 4:31 PM
|CELLULAR DYNAMICS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of|
biz.yahoo.com - March 30 at 3:59 PM
|US STOCKS-Wall St bounces back from recent losses; deals help|
finance.yahoo.com - March 30 at 2:47 PM
|Japan's Fujifilm agrees to buy Cellular Dynamics for $307 mln|
finance.yahoo.com - March 30 at 4:18 AM
Cellular Dynamics International (ICEL) Chart for Monday, July, 24, 2017